“European Panel On Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary

By  

Current Vascular Pharmacology, Vol. 9, Iss. 5, 2011-09 ,pp. : 531-532

Bentham Science Publishers

Access to resources Recommend Favorite

Oxidized low density lipoprotein (LDL) and platelet intracellular calcium: interaction with nitric oxide

By Zuliani R. Tommasoli S. Gaino M. Degan L. Cominacini A. Davoli C. Lechi A. Lechi P. Minuz V.  

Platelets, Vol. 9, Iss. 3-4, 1998-07 ,pp. : 269-272

Informa Healthcare

Access to resources Recommend Favorite

Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]

By  

Current Vascular Pharmacology, Vol. 10, Iss. 2, 2012-03 ,pp. : 173-177

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 3, 2015-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

High‐Density Lipoprotein Subclasses and Noncardiovascular, Noncancer Chronic Inflammatory‐Related Events Versus Cardiovascular Events: The Multi‐Ethnic Study of Atherosclerosis

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 9, 2015-09 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite